Biogen Inc. (VIE:BIIB)
Austria · Delayed Price · Currency is EUR | Market Cap | 23.11B +44.8% |
| Revenue (ttm) | 8.42B +2.2% |
| Net Income | 1.10B -20.8% |
| EPS | 7.49 -21.4% |
| Shares Out | n/a |
| PE Ratio | 20.99 |
| Forward PE | 11.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 6 |
| Open | 157.16 |
| Previous Close | 156.92 |
| Day's Range | 156.18 - 157.16 |
| 52-Week Range | 102.40 - 170.00 |
| Beta | n/a |
| RSI | 50.96 |
| Earnings Date | Apr 29, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment from Chinese biotech firm TJ Biopharma, giving ...
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreem...
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collabora...
Why This Pharma Stock More Than Doubled Today
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.
Biogen Transcript: M&A announcement
The acquisition adds two best-in-class commercial medicines in immunology and rare diseases, expanding the growth portfolio and accelerating nephrology entry. The $5.6B deal is expected to be accretive by 2027, with strong synergy potential and a focus on patient activation and retention.
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy
• Biogen stock is moving in positive territory. Why is BIIB stock advancing?
US FDA approves higher-dose of Biogen's genetic disorder drug
The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, offering patients a potentiall...
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patien...
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people livin...
Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) ...
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taki...
Biogen Transcript: Stifel 2026 Virtual CNS Forum
Key updates include progress in tau-targeting for Alzheimer's, with proof-of-concept trials underway, and a robust pre-symptomatic intervention study expected to read out in 2028. Salanersen shows promise for SMA with multiple Phase 3 trials, while immunology assets like litifilimab, DAPI, and Felza advance in lupus and renal indications.
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy ...
Biogen Transcript: Leerink Global Healthcare Conference 2026
Felzartamab is advancing in four major kidney and autoimmune indications, with phase III trials underway for AMR, IgAN, and PMN, and a phase II for MVI. The AMR program leads with breakthrough designation and a $2B+ U.S. market, while additional autoimmune indications and new formulations are in development.
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen Transcript: TD Cowen 46th Annual Health Care Conference
The organization is executing a multi-year transformation, expanding its late-stage pipeline and launching new products to offset legacy declines. Key growth is expected from Alzheimer's and SMA franchises, with major clinical readouts and product innovations anticipated through 2028.
Biogen Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium
The symposium highlighted a robust immunology pipeline with late-stage lupus programs, differentiated by novel mechanisms and trial designs. Key assets target unmet needs in SLE and CLE, with additional early-stage programs in neuroinflammation and MS, and a multi-indication strategy for future growth.